Acta Pharmaceutica, Vol. 60 No. 4, 2010.
Pregledni rad
https://doi.org/10.2478/v10007-010-0039-2
Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses
SEPTIMIU BUCURESCU
orcid.org/0000-0002-5333-9361
; “Rhoen Klinikum AG” Hospital, 97616 Bad Neustadt ad Saale, Germany
Sažetak
Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.
Ključne riječi
cancer therapies; Herpes simplex virus type 1 glycoproteins E and I; antibody mediated neutralization of oncolytic viruses
Hrčak ID:
59808
URI
Datum izdavanja:
1.12.2010.
Posjeta: 1.538 *